Karyotype complexity and prognosis in acute myeloid leukemia

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F16%3A00064075" target="_blank" >RIV/65269705:_____/16:00064075 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/16:00089323

Result on the web

<a href="http://dx.doi.org/10.1038/bcj.2015.114" target="_blank" >http://dx.doi.org/10.1038/bcj.2015.114</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/bcj.2015.114" target="_blank" >10.1038/bcj.2015.114</a>

Result language

angličtina

Original language name

Karyotype complexity and prognosis in acute myeloid leukemia

Original language description

A complex aberrant karyotype consisting of multiple unrelated cytogenetic abnormalities is associated with poor prognosis in patients with acute myeloid leukemia (AML). The European Leukemia Net classification and the UK Medical Research Council recommendation provide prognostic categories that differ in the definition of unbalanced aberrations as well as the number of single aberrations. The aim of this study on 3526 AML patients was to redefine and validate a cutoff for karyotype complexity in AML with regard to adverse prognosis. Our study demonstrated that (1) patients with a pure hyperdiploid karyotype have an adverse risk irrespective of the number of chromosomal gains, (2) patients with translocation t(9; 11)(p21 similar to 22; q23) have an intermediate risk independent of the number of additional aberrations, (3) patients with }= 4 abnormalities have an adverse risk per se and (4) patients with three aberrations in the absence of abnormalities of strong influence (hyperdiploid karyotype, t(9; 11) (p21 similar to 22; q23), CBF-AML, unique adverse-risk aberrations) have borderline intermediate/adverse risk with a reduced overall survival compared with patients with a normal karyotype.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Blood cancer journal

ISSN

2044-5385

e-ISSN

—

Volume of the periodical

6

Issue of the periodical within the volume

JAN

Country of publishing house

GB - UNITED KINGDOM

Number of pages

7

Pages from-to

"e386"

UT code for WoS article

000369302100010

EID of the result in the Scopus database

—